[go: up one dir, main page]

WO2012068383A3 - Arnnc et utilisations de celui-ci - Google Patents

Arnnc et utilisations de celui-ci Download PDF

Info

Publication number
WO2012068383A3
WO2012068383A3 PCT/US2011/061204 US2011061204W WO2012068383A3 WO 2012068383 A3 WO2012068383 A3 WO 2012068383A3 US 2011061204 W US2011061204 W US 2011061204W WO 2012068383 A3 WO2012068383 A3 WO 2012068383A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
relates
present
ncrna
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/061204
Other languages
English (en)
Other versions
WO2012068383A2 (fr
Inventor
Arul Chinnaiyan
John Prensner
Matthew Iyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Priority to EP11840840.0A priority Critical patent/EP2640854B1/fr
Priority to CN201180065510.1A priority patent/CN103403181B/zh
Priority to AU2011329753A priority patent/AU2011329753B2/en
Priority to CA2818486A priority patent/CA2818486C/fr
Publication of WO2012068383A2 publication Critical patent/WO2012068383A2/fr
Publication of WO2012068383A3 publication Critical patent/WO2012068383A3/fr
Anticipated expiration legal-status Critical
Priority to AU2015242941A priority patent/AU2015242941B2/en
Priority to AU2017276340A priority patent/AU2017276340A1/en
Priority to AU2020201232A priority patent/AU2020201232A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des procédés destinés au diagnostic, à la recherche et à la thérapie contre le cancer, comprenant, mais sans s'y limiter, des marqueurs du cancer. En particulier, la présente invention concerne des ARNnc utilisés comme marqueurs diagnostiques et cibles cliniques pour les cancers de la prostate, des poumons, du sein et du pancréas.
PCT/US2011/061204 2010-11-19 2011-11-17 Arnnc et utilisations de celui-ci Ceased WO2012068383A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP11840840.0A EP2640854B1 (fr) 2010-11-19 2011-11-17 ARNnc PCAT1 ET UTILISATIONS DE CELUI-CI
CN201180065510.1A CN103403181B (zh) 2010-11-19 2011-11-17 ncRNA及其用途
AU2011329753A AU2011329753B2 (en) 2010-11-19 2011-11-17 ncRNA and uses thereof
CA2818486A CA2818486C (fr) 2010-11-19 2011-11-17 Arnnc et utilisations de celui-ci
AU2015242941A AU2015242941B2 (en) 2010-11-19 2015-10-12 ncRNA and uses thereof
AU2017276340A AU2017276340A1 (en) 2010-11-19 2017-12-15 ncRNA and uses thereof
AU2020201232A AU2020201232A1 (en) 2010-11-19 2020-02-20 ncRNA and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41549010P 2010-11-19 2010-11-19
US61/415,490 2010-11-19

Publications (2)

Publication Number Publication Date
WO2012068383A2 WO2012068383A2 (fr) 2012-05-24
WO2012068383A3 true WO2012068383A3 (fr) 2012-08-16

Family

ID=46084653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061204 Ceased WO2012068383A2 (fr) 2010-11-19 2011-11-17 Arnnc et utilisations de celui-ci

Country Status (7)

Country Link
US (4) US20150284802A1 (fr)
EP (2) EP3336200A1 (fr)
CN (2) CN106434870A (fr)
AU (4) AU2011329753B2 (fr)
CA (2) CA2818486C (fr)
HK (1) HK1256822A1 (fr)
WO (1) WO2012068383A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (fr) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Prédiction de l'évolution d'un cancer
EP2806054A1 (fr) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systèmes et procédés de discrimination basés sur l'expression d'états pathologiques cliniques distincts dans le cancer de la prostate
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
EP3336200A1 (fr) 2010-11-19 2018-06-20 The Regents Of The University Of Michigan Arnnc du cancer de la prostate et ses utilisations
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (fr) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Diagnostics du cancer à l'aide de transcriptions non codantes
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
CN103146688B (zh) * 2012-09-12 2015-05-13 上海长海医院 长链非编码rna作为疾病诊断血液分子标志物的应用
WO2014152355A2 (fr) * 2013-03-14 2014-09-25 The Broad Institute, Inc. Marqueurs de risque associés à l'ostéosarcome et leurs utilisations
WO2014205555A1 (fr) * 2013-06-28 2014-12-31 British Columbia Cancer Agency Branch Procédés et utilisations pour diagnostiquer et traiter le cancer de la prostate
WO2015120022A1 (fr) * 2014-02-04 2015-08-13 Thomas Jefferson University Expression spécifique de demi-arnt dans les cancers
WO2016087430A1 (fr) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Nouveaux biomarqueurs d'arn signatures pour le diagnostic du cancer de la prostate
CN106047876B (zh) * 2015-06-04 2018-11-02 佛山市第一人民医院 一种鼻咽癌相关分子标志物及其应用
CN106047875B (zh) * 2015-06-04 2018-11-02 佛山市第一人民医院 lncRNA分子及其在鼻咽癌辅助诊断中的应用
CN105936904B (zh) * 2015-06-04 2018-07-20 佛山市第一人民医院 lncRNA分子ENST00000438553及其在鼻咽癌辅助诊断中的应用
WO2017103047A1 (fr) * 2015-12-17 2017-06-22 Institut Curie Utilisation d'arn antisens longs non codants destinés au diagnostic du cancer de la prostate
US20190144951A1 (en) * 2016-06-08 2019-05-16 Mir Scientific, Llc Methods and compositions for prostate cancer diagnosis and treatment
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (fr) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Signatures génétiques pour prédire une métastase du cancer de la prostate et identifier la virulence d'une tumeur
WO2019036682A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Variants d'arn polymérase
CN107729719B (zh) * 2017-09-30 2020-05-26 中国科学院计算技术研究所 一种从头测序方法
CN111344409A (zh) * 2017-11-12 2020-06-26 加利福尼亚大学董事会 用于检测癌症的非编码rna
CN108998531B (zh) * 2018-08-31 2021-10-01 昆明医科大学第一附属医院 肺癌下调长链非编码rna标志物及其应用
CN108998530B (zh) * 2018-08-31 2021-10-08 昆明医科大学第一附属医院 肺癌上调长链非编码rna标志物及其应用
WO2023152568A2 (fr) * 2022-02-10 2023-08-17 Oslo Universitetssykehus Hf Compositions et méthodes de caractérisation du cancer du poumon
CN114480651B (zh) * 2022-02-14 2023-10-20 天津市泌尿外科研究所 Pcat1的反义寡核苷酸及其在制备抑制前列腺癌核酸药物中的应用
KR20250141769A (ko) * 2023-01-30 2025-09-29 더 리젠츠 오브 더 유니버시티 오브 미시건 전립선암을 예후, 진단 및 치료하는데 유용한 키트 및 방법
CN119614581A (zh) * 2024-12-11 2025-03-14 中国人民解放军海军军医大学第一附属医院 一种增加腺相关病毒介导spink1基因表达的内含子及其在体内胰腺炎治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0232967B1 (fr) 1986-01-10 1993-04-28 Amoco Corporation Dosage homogène concomitant
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
CA2020958C (fr) 1989-07-11 2005-01-11 Daniel L. Kacian Methodes d'amplification de sequences d'acide nucleique
ATE282716T1 (de) 1989-07-11 2004-12-15 Gen Probe Inc Verfahren zur amplifikation von nukleinsäuresequenzen
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
EP0914335A2 (fr) 1996-03-15 1999-05-12 Corixa Corporation Composes et methodes d'immunotherapie et d'immunodiagnostic pour le cancer de la prostate
DE69738687D1 (de) 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1005546A2 (fr) 1997-02-25 2000-06-07 Corixa Corporation Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
WO1998039636A1 (fr) 1997-03-07 1998-09-11 Clare Chemical Research Llc Detection fluorimetrique au moyen de lumiere visible
ES2324503T3 (es) * 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US20030044783A1 (en) * 2000-03-09 2003-03-06 Williams Lewis T. Human genes and gene expression products
WO2000001850A2 (fr) 1998-07-02 2000-01-13 Gen-Probe Incorporated Torches moleculaires
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6541205B1 (en) 1999-05-24 2003-04-01 Tosoh Corporation Method for assaying nucleic acid
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003023057A2 (fr) 2001-09-06 2003-03-20 Adnagen Ag Procede et kit de diagnostic destines a la selection et/ou detection qualitative et/ou quantitative de cellules
EP1578919B1 (fr) * 2001-12-07 2010-02-17 Novartis Vaccines and Diagnostics, Inc. Retrovirus endogene regule positivement dans le cancer de la prostate
CA2524572C (fr) 2003-05-01 2018-07-10 Gen-Probe Incorporated Oligonucleotides comprenant un systeme de commutation moleculaire ayant une sensibilite accrue a la presence d'un mesappariement
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
US7696337B2 (en) 2004-08-27 2010-04-13 Gen-Probe Incorporated Composition kits and methods for performing amplification reactions
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20070172841A1 (en) * 2006-01-25 2007-07-26 Hui Wang Probe/target stabilization with add-in oligo
US20110045464A1 (en) * 2007-01-10 2011-02-24 Henry Ford Health System Methods and compositions for identification of prostate cancer markers
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3336200A1 (fr) 2010-11-19 2018-06-20 The Regents Of The University Of Michigan Arnnc du cancer de la prostate et ses utilisations
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUSSEMAKERS, M. J. ET AL.: "DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.", CANCER RESEARCH., vol. 59, no. 23, 1 December 1999 (1999-12-01), pages 5975 - 5979, XP002923011 *
FU, X. ET AL.: "Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene", PCGEM1. DNA AND CELL BIOLOGY., vol. 25, no. 3, March 2006 (2006-03-01), pages 135 - 141, XP055107442 *
PRENSNER, J. R. ET AL.: "Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.", NATURE BIOTECHNOLOGY, vol. 29, no. 8, 31 July 2011 (2011-07-31), pages 742 - 749, XP055106101 *
TAFT, R. J. ET AL.: "Non-coding RNAs: regulators of disease.", THE JOURNAL OF PATHOLOGY., vol. 220, no. 2, January 2010 (2010-01-01), pages 126 - 139, XP055107448 *

Also Published As

Publication number Publication date
CA3012765A1 (fr) 2012-05-24
US20200165682A1 (en) 2020-05-28
WO2012068383A2 (fr) 2012-05-24
AU2011329753B2 (en) 2015-07-23
US11390923B2 (en) 2022-07-19
AU2017276340A1 (en) 2018-01-18
CA2818486C (fr) 2018-09-11
US20160251729A1 (en) 2016-09-01
EP2640854A2 (fr) 2013-09-25
HK1256822A1 (en) 2019-10-04
AU2015242941B2 (en) 2017-12-21
CN106434870A (zh) 2017-02-22
US20150284802A1 (en) 2015-10-08
EP3336200A1 (fr) 2018-06-20
CN103403181A (zh) 2013-11-20
EP2640854B1 (fr) 2018-02-21
AU2015242941A1 (en) 2015-10-29
CN103403181B (zh) 2016-09-07
EP2640854A4 (fr) 2014-05-07
CA2818486A1 (fr) 2012-05-24
US20230016456A1 (en) 2023-01-19
AU2011329753A1 (en) 2013-06-06
AU2020201232A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
WO2012068383A3 (fr) Arnnc et utilisations de celui-ci
WO2012174256A3 (fr) Profils de méthylation de l'adn dans le cancer
WO2010081001A3 (fr) Fusions de gène récurrent dans le cancer
WO2011034906A3 (fr) Fusions de gène récurrentes dans le cancer de la prostate
WO2013089882A3 (fr) Fusions de gènes récurrentes dans le cancer du sein
WO2012158780A3 (fr) Signature du cancer du poumon
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2012006421A3 (fr) Diagnostic et traitement du cancer du sein
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2012170776A3 (fr) Procédés de détermination du pronostic d'un patient pour la récurrence d'un cancer de la prostate et/ou déterminer une évolution de traitement pour un cancer de la prostate après une prostatectomie radicale
WO2013025952A3 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer du sein
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2011103016A3 (fr) Compositions et méthodes d'inhibition d'ezh2
EP3683320A3 (fr) Empreinte arnmi dans le diagnostic de cancer du poumon
WO2011008696A3 (fr) Procédés de diagnostic et compositions pour traitement d'un cancer
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2012083969A3 (fr) Microarn pour le diagnostic du cancer du pancréas
WO2011002834A3 (fr) Compositions et procédés de diagnostic et de traitement du diabète de type i
WO2009103741A3 (fr) Utilisation de ligands des récepteurs de la fsh pour diagnostiquer et traiter le cancer
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2010101793A3 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840840

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2818486

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011329753

Country of ref document: AU

Date of ref document: 20111117

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011840840

Country of ref document: EP